JP2024534427A - 血栓塞栓性障害を予防かつ治療するためのミルベキシアン - Google Patents

血栓塞栓性障害を予防かつ治療するためのミルベキシアン Download PDF

Info

Publication number
JP2024534427A
JP2024534427A JP2024516849A JP2024516849A JP2024534427A JP 2024534427 A JP2024534427 A JP 2024534427A JP 2024516849 A JP2024516849 A JP 2024516849A JP 2024516849 A JP2024516849 A JP 2024516849A JP 2024534427 A JP2024534427 A JP 2024534427A
Authority
JP
Japan
Prior art keywords
milbexian
acceptable salt
pharma
daily dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534427A5 (https=
Inventor
ストロニー，ジョン
ピーターズ，ゲイリー
チンタラ，マドゥ
ネッセル，クリストファー
ビドヤ ペレラ，リヤナゲ
リィ，ダンシ
エム リュートゲン，ジョセフ
アルフレート ザイフェルト，ディートマル
ジョーンズ－バートン，シャーロット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024534427A publication Critical patent/JP2024534427A/ja
Publication of JP2024534427A5 publication Critical patent/JP2024534427A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024516849A 2021-09-17 2022-09-16 血栓塞栓性障害を予防かつ治療するためのミルベキシアン Pending JP2024534427A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US63/245,522 2021-09-17
US202163278582P 2021-11-12 2021-11-12
US63/278,582 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (2)

Publication Number Publication Date
JP2024534427A true JP2024534427A (ja) 2024-09-20
JP2024534427A5 JP2024534427A5 (https=) 2025-09-25

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516849A Pending JP2024534427A (ja) 2021-09-17 2022-09-16 血栓塞栓性障害を予防かつ治療するためのミルベキシアン

Country Status (11)

Country Link
US (1) US20250099466A1 (https=)
EP (1) EP4401736A1 (https=)
JP (1) JP2024534427A (https=)
KR (1) KR20240060820A (https=)
AU (1) AU2022345862A1 (https=)
CA (1) CA3232633A1 (https=)
CL (1) CL2024000776A1 (https=)
IL (1) IL310894A (https=)
MX (1) MX2024002857A (https=)
TW (1) TW202327607A (https=)
WO (1) WO2023043999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) * 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
TW202506125A (zh) * 2023-04-19 2025-02-16 美商必治妥美雅史谷比公司 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation
EP4698172A1 (en) * 2023-04-19 2026-02-25 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Also Published As

Publication number Publication date
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
KR20240060820A (ko) 2024-05-08
EP4401736A1 (en) 2024-07-24
CA3232633A1 (en) 2023-03-23
US20250099466A1 (en) 2025-03-27
WO2023043999A1 (en) 2023-03-23
TW202327607A (zh) 2023-07-16
MX2024002857A (es) 2024-03-21

Similar Documents

Publication Publication Date Title
JP2024534427A (ja) 血栓塞栓性障害を予防かつ治療するためのミルベキシアン
JP7335397B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドの組成物
TW201022237A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
TW201031651A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
JPWO2010071164A1 (ja) 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
JP2024541514A (ja) 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ
CN119816305A (zh) Milvexian在治疗或预防缺血性中风中的用途
JP2024543161A (ja) 進行性線維化を伴う間質性肺疾患を治療するための、新たな経口医薬組成物及び投与レジメン
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
JP2008543853A (ja) プラスグレルのための薬剤投与計画
JP2019178177A (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
CN118302166A (zh) 用于预防及治疗血管栓塞病症的米尔维仙
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
Cui et al. Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent
AU2005239799B2 (en) Sustained-release oral molsidomine composition for treating atherosclerosis
CA2993858A1 (en) Combination of rivaroxaban and acetylsalicylic acid for reducing the risk of cardiovascular events
TW202506124A (zh) 米爾維仙(milvexian)於治療或預防患有急性冠狀動脈症候群之患者之不良腦血管事件或不良心血管事件的用途
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
MXPA04001174A (es) Tratamiento para lipodistrofia.
TW201219404A (en) Reversal agents for the anticoagulant effect
JP2024518110A (ja) 去勢抵抗性前立腺癌の治療のためのマシチニブ
JP2011528345A (ja) 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用
US20150065456A1 (en) Agent for treatment and prevention of cancer
EP3328386A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
HK1177139A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250912